BLAINHALATIONPOWDER
Approved
Jun 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
6/8 — Strong
AFREZZA (insulin human) by Eli Lilly and Company is fat, and by inhibiting hepatic glucose production. Approved for diabetes mellitus, type 1, diabetes mellitus, type 2, diabetes mellitus. First approved in 2014.
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AFREZZA is an inhaled human insulin powder approved by the FDA in June 2014 for glycemic control in adult patients with diabetes mellitus. It represents a novel non-injectable insulin delivery route designed to improve patient adherence and quality of life. The drug works through the classical insulin mechanism: lowering blood glucose by stimulating glucose uptake in muscle and fat tissue, inhibiting hepatic glucose production, and promoting anabolic processes including protein synthesis. AFREZZA offers a differentiated position in the insulin market as the only rapid-acting inhaled insulin currently available.
$0.0BPart D
Mechanism of Action
fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.
Pharmacologic Class:
Insulin
Indications (3)
Worked on AFREZZA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.